AbbVie Inc. (ABBV) - Stock Analysis

Last updated: Jan 18, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential.

Loading chart data...

Idea window: 9/29/2025 – 10/6/2025Sector: Healthcare

AI Analyst Overview

Last Price

$214.35

Market Cap

$378837.90

1D Return

-0.31%

YTD Return

-5.44%

Loading chart data...

Valuation Metrics

P/E

158.7

P/B

-143.8

P/S

6.3

EV/EBITDA

35.2

Div Yield

3.10%

Fundamental Analysis

6.0

Key Financial Insights: • High cash generation • Earnings compression • Negative equity AbbVie generates strong gross margins and cash flow supporting its dividend, but sharp earnings compression, rising leverage and negative equity alongside rich valuation multiples materially increase downside risk.

Leverage

MixedSignals

Price Behavior

6.0

Key Price Behavior Insights: • Steady lower closes • Weak bounce • Support testing Support Level: $214–215 Resistance Level: $228–230 Over the last month ABBV has slid from above $228 to about $214, holding short-term support near $214–215 but showing a bearish bias and risk of further decline if $214 breaks.

bearish

watch

Sentiment & News

6.0

Key News Insights: • Strong product momentum • Affordability deal • Valuation pressure AbbVie's strong 2025 earnings and investor backing—driven by Skyrizi/Rinvoq and a $5.6B oncology deal—are tempered by valuation pressure, pipeline uncertainty and a major U.S. affordability pact that includes pricing concessions.

Resilient

PolicyShift

AI Summary

6.0

Neutral

AbbVie has pivoted from a Humira‑replacement income play into a high‑investment, leveraged growth operator—trading short‑term margins and earnings stability for a $100B R&D/capex and oncology build—so shift from buy‑and‑hold income to a conditional, event‑driven stance tied to Skyrizi/Rinvoq momentum, pivotal oncology readouts, and demonstrable margin and net‑debt stabilization (sustained FCF conversion, falling net leverage, no further material IPR&D write‑downs).

Pipeline

Leverage

Execution

AI summary updated today

Description

AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinson’s and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.

Idea History

Date	Close	Ticker	Company	Summary	Status	P/L
Sep 29	Oct 6	ABBV	AbbVie Inc.	AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential.	Closed	+3.1%

People also watch

Alumis Inc. Common Stock

ALMS

+35.8%

Krystal Biotech, Inc.

KRYS

+0.9%

Adaptive Biotechnologies Corporation

ADPT

-8.0%